PMID- 34295820
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220425
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Zusanli (ST36) Acupoint Injection With Dexamethasone for Chemotherapy-Induced 
      Myelosuppression: A Systematic Review and Meta-Analysis.
PG  - 684129
LID - 10.3389/fonc.2021.684129 [doi]
LID - 684129
AB  - OBJECTIVE: Myelosuppression is the most common adverse reaction of chemotherapy, 
      which seriously affects the course of treatment. Zusanli (ST36) acupoint 
      injection with dexamethasone has achieved good clinical efficacy in China. This 
      study aimed to systematically evaluate the efficacy of ST36 acupoint injection 
      with dexamethasone in the treatment of chemotherapy-induced myelosuppression 
      (CIM). METHODS: Randomized controlled trials of CIM treated with ST36 acupoint 
      injection with dexamethasone were retrieved from eight electronic databases. We 
      used the Cochrane Collaboration tool to assess the risk of bias. Excel 2010 was 
      used to establish a database for information extraction, and RevMan 5.3.0 
      software was used to analyze the included test data. GRADE profiler 3.6 software 
      was used to grade the quality of evidence for the outcome indicators of the 
      study. RESULTS: A total of 17 studies involving 1177 patients were included in 
      this meta-analysis. The results showed that, compared with conventional western 
      medicine (CWM), ST36 acupoint injection with dexamethasone could significantly 
      improve the clinical total effective rate [RR=1.95, 95% CI (1.53, 2.49), P 
      <0.00001] and increase white blood cell (WBC) (MD=1.38, 95% CI (0.74, 2.01), 
      P<0.0001) and hemoglobin (Hb) levels [MD=3.89, 95% CI (1.57, 6.20), P=0.001]. In 
      addition, ST36 acupoint injection with dexamethasone can shorten recovery time of 
      myelosuppression [MD=-3.94, 95% CI (-4.97 to -2.91), P<0.00001] and improve 
      Karnofsky performance status [MD=10.7, 95% CI (1.36, 20.05), P=0.02<0.05]. 
      However, there was no significant difference among ST36 acupoint injection with 
      dexamethasone and CWM in platelet (PLT) elevation [MD=4.61, 95% CI (-10.14, 
      19.35), P=0.54]. CONCLUSION: This study found that ST36 acupoint injection with 
      dexamethasone had a positive effect on CIM. However, more studies with 
      well-designed, large sample size, strict randomization, and clear descriptions 
      about detection and reporting processes are needed in the future to further 
      confirm the efficacy of ST36 acupoint injection with dexamethasone in the 
      treatment of CIM. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/, 
      identifier CRD42021223979.
CI  - Copyright (c) 2021 Chen, Lin and Ding.
FAU - Chen, Jiangfeng
AU  - Chen J
AD  - Department of Integrated Traditional Chinese & Western Medicine Oncology Ward 1, 
      Hangzhou Cancer Hospital, Hangzhou, China.
FAU - Lin, Zhixian
AU  - Lin Z
AD  - Department of Oncology, The Third People's Hospital of Hangzhou, Hangzhou, China.
FAU - Ding, Jiyuan
AU  - Ding J
AD  - Department of Integrated Traditional Chinese & Western Medicine Oncology Ward 1, 
      Hangzhou Cancer Hospital, Hangzhou, China.
LA  - eng
PT  - Systematic Review
DEP - 20210706
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8291031
OTO - NOTNLM
OT  - acupoint injection
OT  - chemotherapy
OT  - dexamethasone
OT  - meta-analysis
OT  - myelosuppression
OT  - zusanli (ST36)
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/07/24 06:00
MHDA- 2021/07/24 06:01
PMCR- 2021/01/01
CRDT- 2021/07/23 06:51
PHST- 2021/03/22 00:00 [received]
PHST- 2021/06/11 00:00 [accepted]
PHST- 2021/07/23 06:51 [entrez]
PHST- 2021/07/24 06:00 [pubmed]
PHST- 2021/07/24 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.684129 [doi]
PST - epublish
SO  - Front Oncol. 2021 Jul 6;11:684129. doi: 10.3389/fonc.2021.684129. eCollection 
      2021.